GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end of earnings guidance for the year. The bounce-back wasn’t… Read More »Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares
Eli Lilly has asked the FDA for an Emergency Use Authorization for its COVID-19 antibody therapy, after announcing new efficacy data from an ongoing trial. It’s been a big week for this class of therapies – Regeneron’s antibody cocktail was famously used to treat president… Read More »Lilly asks FDA for emergency clearance for COVID-19 antibody therapy
GlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting heat on Regeneron’s rival that has been famously used to treat president Donald Trump. GSK and Vir began trials of the antibody on early-stage COVID-19 patients in… Read More »GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rival
Drugs company says infection controls at some of its sites are so secure the app is not needed Coronavirus – latest updates See all our coronavirus coverage The pharmaceuticals firm GlaxoSmithKline has told staff to switch off the contact tracing function that allows the NHS… Read More »GSK tells UK staff: turn off Covid test-and-trace app while at work
World’s largest vaccine makers to begin testing on people in US with eye on rollout in early 2021 Coronavirus – latest updates See all our coronavirus coverage GlaxoSmithKline and Sanofi are to start testing their protein-based Covid-19 vaccine on humans for the first time, following… Read More »GSK and Sanofi to start human trials of potential Covid-19 vaccine
An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease. HBV affects an estimated 260 million people worldwide, according to GSK. While drugs to… Read More »Ionis deal delivers for GSK as HBV drug hits the mark in phase 2
GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission. Blenrep (belantamab mafodotin) becomes the first BCMA-targeted drug for myeloma to be approved in the EU, and according to its label can… Read More »GSK moves further ahead in BCMA with EU okay for Blenrep
Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.
The US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 vaccine development initiative, committing up to $2.1 billion for an initial 100 million doses. The collaborative effort with the US government will accelerate the development and manufacturing… Read More »US pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccine
The companies will provide 100 million doses of their jointly developed vaccine. But with a Phase I/II study planned in September, it is behind in development compared with those of Moderna and Pfizer and BioNTech, which have already started late-stage clinical testing.
Companies can return to work from 1 August, but many employers are making their own plans Companies ready to defy Boris Johnson’s planned return to work Future shape of offices: proposals to make workplaces safe Major companies in England have been told that, from 1… Read More »Return to work: a sector-by-sector look at the plans of England’s major employers
AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic. AZ’s second quarter sales increased by 8% compared with the same period last year to just under $6.3 billion.… Read More »AstraZeneca beats expectations in Q2, while GSK struggles during pandemic
The UK government has signed its fourth coronavirus vaccine deal, snapping up 60 million doses of an experimental shot being developed by Sanofi and GlaxoSmithKline. The order has come in even before the vaccine has started clinical development, with a phase 1/2 trial not due… Read More »UK places order for 60m doses of Sanofi/GSK’s COVID-19 vaccine
GlaxoSmithKline and Sanofi Pasteur could supply vaccine by early next year if it is successful Coronavirus – latest updates See all our coronavirus coverage The government has signed a deal with the pharmaceutical firms GlaxoSmithKline (GSK) and Sanofi Pasteur for 60m doses of a potential… Read More »Coronavirus: UK signs deal for 60m doses of potential vaccine
GlaxoSmithKline is closing in on EU approval for its first-in-class BCMA-targeting drug Blenrep, after getting a green light from the EMA’s human medicines committee. Blenrep, based on the antibody-drug conjugate belantamab mafodotin, has been recommended for conditional approval by the CHMP in adult patients with… Read More »CHMP gives nod to GSK’s BCMA drug Blenrep for myeloma
AstraZeneca and GSK both release results this week. But picking winners in the sector may be complicated It was the press announcement heard around the world: a potential Covid-19 vaccine from the University of Oxford and pharmaceutical company AstraZeneca had not only been “tolerated” by… Read More »Covid-19 is Big Pharma’s chance to impress. But who’ll do best?
AstraZeneca’s triple therapy for chronic obstructive pulmonary disease (COPD), Breztri Aerosphere (budesonide+glycopyrrolate+formoterol fumarate), has been approved in the US following a rejection last year. Approval follows a rejection by the FDA in October last year after the FDA refused to grant a licence based on… Read More »AZ’s COPD triple therapy approved in the US
GSK’s share price has been left standing by AstraZeneca’s high-risk success in cancer treatments Monday’s most important vaccine news was the promising early data from the Oxford University and AstraZeneca coronavirus trial – “robust immune responses” is encouraging. But let’s not overlook other vaccine developments.… Read More »GlaxoSmithKline makes bold move with £130m Covid-19 investment | Nils Pratley
Stake of 10% in CureVac is part of deal that could eventually be worth more than £800m Coronavirus – latest updates See all our coronavirus coverage The British pharmaceutical company GlaxoSmithKline has bought a 10% stake in a German biotech company that is a key… Read More »GSK buys £130m stake in German coronavirus vaccine maker
The UK has secured 90 million doses of two different COVID-19 vaccines from BioNTech/Pfizer and Valneva, with an option of 40 million doses if they check out in trials. There is no approved COVID-19 vaccine, but governments across the world are busy signing deals with developers to gain access should trial results… Read More »UK announces COVID-19 vaccine deals with BioNTech/Pfizer and Valneva
The Oncologic Drugs Advisory Committee voted 12-0 that the benefit-risk profile of belantamab mafodotin supported the drug. The vote came despite concerns expressed by the FDA in briefing documents ahead of the ODAC meeting, particularly with regard to ocular toxicity.
The FDA’s Oncologic Drugs Advisory Committee will convene Tuesday to discuss the drug, belantamab mafodotin. Despite the drug’s first-in-class potential, the briefing document for the meeting raised concerns about eye toxicity and questions about its risk-benefit profile.
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead’s Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.
